LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
Summary
Leidos Holdings ($LDOS) received a $484M delivery order from NIH for NCI operations, representing ~1.6% of annual revenue. This contract is supported by legislative efforts to strengthen cancer research (S5554) and biotech infrastructure (S5502). The award reinforces Leidos' position in federal healthcare IT and research services.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Leidos secures $484M NIH task order for cancer research operations, adding ~$242M annual revenue.
- 2.Legislative support for cancer research (S5554) and biotech infrastructure (S5502) provides tailwinds for continued federal investment.
- 3.The contract reinforces Leidos' position as a leading provider of biomedical research support services to the federal government.
Market Implications
Leidos' stock may see modest upside from this award as it reinforces its role in federal health IT. The broader healthcare IT sector, including companies like IQVIA ($IQV), could benefit from increased NIH funding. However, the impact is incremental given Leidos' size and the contract's nature as a task order under an existing vehicle.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, awarded a $484M delivery order to Leidos Biomedical Research Inc. for operational support of the National Cancer Institute (NCI) for fiscal years 2026-2027. This task order covers a range of services including research administration, IT support, and program management for NCI's cancer research initiatives.
Leidos Biomedical Research Inc. is a wholly-owned subsidiary of Leidos Holdings ($LDOS), a publicly traded defense and healthcare IT services company. With annual revenue of $15.3B (FY2025), this $484M contract adds approximately $242M per year, a 1.6% revenue boost. While not transformative, it provides predictable cash flow and demonstrates Leidos' continued partnership with NIH. Leidos' health segment has been a growth driver, and this award solidifies its role in federal biomedical research.
Legislative tailwinds support this contract. S5554, a bill to enhance ovarian cancer awareness and genetic counseling, directly aligns with NCI's mission and could lead to expanded programs and future task orders. S5502, focused on protecting biotechnology infrastructure, signals sustained federal investment in the biotech sector, benefiting companies like Leidos that operate in this space. These bills, while not directly appropriating funds for this specific order, indicate congressional support for cancer research and biotech resilience.
Downstream, subcontractors and suppliers may benefit. Clinical research organizations such as IQVIA ($IQV) and laboratory service providers could see increased demand as NCI operations expand. However, the primary impact is on Leidos itself, as the prime contractor.
Historically, Leidos has consistently won large task orders from NIH, contributing to its stable revenue base in health and civil markets. Similar awards have historically supported Leidos' stock performance due to predictable cash flows and strong government relationships. Investors should view this as a positive but incremental development for Leidos.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award of a delivery order for NCI operational support services.
Who must act
Department of Health and Human Services, National Institutes of Health (NIH) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings.
What happens
$484M added to Leidos' contract backlog over FY2026-FY2027, representing approximately $242M in annual revenue, or ~1.6% of Leidos' FY2025 revenue of $15.3B.
Stock impact
Leidos' health and civil segment, which includes biomedical research services, will see a direct revenue boost. The contract reinforces Leidos' position as a key NIH partner and provides stable, multi-year cash flows. Given Leidos' net margin of 1.3% in FY2025, this contract could contribute modestly to profitability.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend the Homeland Security Act of 2002 to provide for the protection of biotechnology and biomanufacturing infrastructure by the Cybersecurity and Infrastructure Security Agency of the Department of Homeland Security, and for other purposes.
A bill to modernize and strengthen Federal efforts to improve ovarian cancer awareness, hereditary cancer risk assessment, access to genetic counseling and testing, and access to specialty care, and for other purposes.
Department of Homeland Security Appropriations Act, 2027
LEIDOS BIOMEDICAL RESEARCH INC: $342M Department of Health and Human Services Contract
LEIDOS, INC.: $458M Department of Homeland Security Contract
QTC MEDICAL SERVICES INC: $336M Department of Veterans Affairs Contract
LEIDOS, INC.: $422M Department of Homeland Security Contract
Slash the Pentagon Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
RESTORING AMERICAN SALTWATER ANGLING AND RECREATION
This executive order directs federal agencies (primarily NOAA and the Department of Commerce) to shift fisheries management toward prioritizing recreational fishing over commercial interests by modernizing data collection, replacing outdated mail-in surveys with real-time mobile reporting, and allowing state-collected data to substitute for federal data when error rates are lower. It also mandates reviewing and potentially revising National Standards under the Magnuson-Stevens Act, rescinding regulations that restrict marine access, and launching pilot programs for iconic fisheries like Atlantic striped bass, with the goal of boosting the $1.2 trillion outdoor recreation sector.
Contract Details
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$483,791,548
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Related Bills
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →